Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 6 studies | 32% ± 15% | |
macrophage | 6 studies | 24% ± 9% | |
glutamatergic neuron | 4 studies | 31% ± 20% | |
oligodendrocyte | 4 studies | 33% ± 18% | |
GABAergic neuron | 3 studies | 30% ± 20% | |
enterocyte | 3 studies | 20% ± 4% | |
enteroendocrine cell | 3 studies | 25% ± 8% | |
endothelial cell | 3 studies | 19% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 40% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 2096.82 | 653 / 653 | 94% | 22.61 | 566 / 605 |
prostate | 96% | 586.43 | 235 / 245 | 98% | 38.66 | 490 / 502 |
stomach | 92% | 1915.64 | 331 / 359 | 96% | 18.13 | 275 / 286 |
breast | 96% | 565.03 | 440 / 459 | 89% | 14.14 | 995 / 1118 |
intestine | 78% | 791.35 | 757 / 966 | 95% | 16.13 | 502 / 527 |
lung | 98% | 589.65 | 569 / 578 | 75% | 8.30 | 867 / 1155 |
uterus | 95% | 431.37 | 162 / 170 | 64% | 8.24 | 293 / 459 |
pancreas | 60% | 156.18 | 196 / 328 | 90% | 11.77 | 160 / 178 |
esophagus | 70% | 191.92 | 1006 / 1445 | 68% | 15.42 | 124 / 183 |
bladder | 81% | 218.86 | 17 / 21 | 51% | 6.10 | 258 / 504 |
skin | 81% | 2226.30 | 1461 / 1809 | 39% | 2.52 | 182 / 472 |
spleen | 100% | 976.37 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 99% | 819.62 | 1188 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 92% | 661.59 | 857 / 929 | 0% | 0 | 0 / 0 |
brain | 77% | 350.01 | 2030 / 2642 | 11% | 0.80 | 76 / 705 |
ovary | 27% | 64.17 | 49 / 180 | 59% | 3.76 | 255 / 430 |
kidney | 48% | 136.78 | 43 / 89 | 29% | 2.61 | 265 / 901 |
lymph node | 0% | 0 | 0 / 0 | 72% | 5.18 | 21 / 29 |
blood vessel | 71% | 249.53 | 948 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 62% | 4.22 | 28 / 45 |
adrenal gland | 51% | 110.72 | 132 / 258 | 8% | 0.53 | 18 / 230 |
heart | 53% | 155.25 | 459 / 861 | 0% | 0 | 0 / 0 |
liver | 12% | 24.29 | 28 / 226 | 6% | 0.64 | 24 / 406 |
eye | 0% | 0 | 0 / 0 | 6% | 0.23 | 5 / 80 |
muscle | 5% | 8.46 | 37 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0016266 | Biological process | O-glycan processing |
GO_0060352 | Biological process | cell adhesion molecule production |
GO_0060993 | Biological process | kidney morphogenesis |
GO_0032868 | Biological process | response to insulin |
GO_0016268 | Biological process | O-glycan processing, core 2 |
GO_1903238 | Biological process | positive regulation of leukocyte tethering or rolling |
GO_0048729 | Biological process | tissue morphogenesis |
GO_0009101 | Biological process | glycoprotein biosynthetic process |
GO_0050901 | Biological process | leukocyte tethering or rolling |
GO_0005802 | Cellular component | trans-Golgi network |
GO_0005615 | Cellular component | extracellular space |
GO_0000139 | Cellular component | Golgi membrane |
GO_0031985 | Cellular component | Golgi cisterna |
GO_0016020 | Cellular component | membrane |
GO_0003829 | Molecular function | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | GCNT1 |
Protein name | Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase (EC 2.4.1.102) (Core 2 beta-1,6-N-acetylglucosaminyltransferase) (C2GlcNAcT) (Core 2-branching enzyme) (Core2-GlcNAc-transferase) (C2GNT) (Core 2 GNT) (Leukocyte type core 2 beta-1,6-N-acetylglucosaminyltransferase) (C2GnT-L) Alternative protein GCNT1 |
Synonyms | NACGT2 |
Description | FUNCTION: Glycosyltransferase that catalyzes the transfer of an N-acetylglucosamine (GlcNAc) moiety in beta1-6 linkage from UDP-GlcNAc onto mucin-type core 1 O-glycan to form the branched mucin-type core 2 O-glycan . The catalysis is metal ion-independent and occurs with inversion of the anomeric configuration of sugar donor (By similarity). Selectively involved in synthesis of mucin-type core 2 O-glycans that serve as scaffolds for the display of selectin ligand sialyl Lewis X epitope by myeloid cells, with an impact on homeostasis and recruitment to inflammatory sites (By similarity). Can also act on glycolipid substrates. Transfers GlcNAc moiety to GalGb4Cer globosides in a reaction step to the synthesis of stage-specific embryonic antigen 1 (SSEA-1) determinant (By similarity). Can use Galbeta1-3GalNAcalpha1- and Galbeta1-3GalNAcbeta1- oligosaccharide derivatives as acceptor substrates (By similarity). . |
Accessions | ENST00000376730.5 L8E8T5 Q02742 ENST00000444201.6 ENST00000442371.5 |